Basal Cell Carcinoma, Squamous Cell Carcinoma
Conditions
Keywords
Electronic, Brachytherapy, Nonmelanoma, cancer
Brief summary
The objective of this study is to record recurrence in patients treated for nonmelanoma (basal cell and squamous cell carcinomas) skin cancer using the Xoft Axxent Electronic Brachytherapy System. Additional objectives include evaluate the appearance of the treated area in patients treated for nonmelanoma skin cancer using the Xoft Axxent Electronic Brachytherapy System and record the occurrence of radiation therapy related skin changes in patients treated for nonmelanoma skin cancer.
Detailed description
The objective of this study is to record local recurrence in patients treated for nonmelanoma (basal cell and squamous cell carcinomas) skin cancer using the Xoft Axxent Electronic Brachytherapy System. Additional objectives include evaluate the cosmetic outcomes in patients treated for nonmelanoma skin cancer using the Xoft Axxent Electronic Brachytherapy System and record the occurrence of radiation therapy related skin toxicities in patients treated for nonmelanoma skin cancer using the Xoft Axxent Electronic Brachytherapy System.
Interventions
RADIATIONelectronic brachytherapy
Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
Sponsors
Xoft, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient has signed the informed consent form * Pathological diagnosis confirmed of squamous cell or basal cell carcinoma * Histopathological Grade: G1 (well differentiated), G2 (moderately differentiated), or Gx (Not assessed in report) * Clinical Staging Tis, T1, or T2 (Must be ≤ 4 cm in diameter) * One lesion is treated, or more than 1 lesion is treated with a minimum of a 5 mm gap between the edges of the lesion margins.
Exclusion criteria
* T2 \> 4 cm and T3 and T4 * American Joint Committee Staging for NMSC Stages III and IV * Histopathologic Grade 3 (poorly differentiated) or higher grade * Target area is adjacent to a burn scar * Target area is on the lip * Patient \< 50 years of age * Any prior definitive surgical resection of the cancer * Perineural invasion * Lesion depth \> 5mm on clinical assessment or as assessed by ultrasound or CT. * Patient is pregnant (pregnancy test required if standard of care). * Target area is prone to trauma. * Target area with compromised lymphatic or vascular drainage. * Participation in another investigational device or drug study concurrently. * Patient has undergone prior radiation therapy to this specific anatomic location. * Patient is receiving pharmacologic agent(s) at or around the time of the Radiation therapy that is/are known to produce skin reactions that will influence cosmesis grading during study. * Patient is receiving chemotherapeutic agent(s) Six (6) weeks before or six (6) weeks after radiation therapy. * Life expectancy less than five (5) years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local recurrence of NMSC | at six (6) months, one (1) year, two (2) years, three (3) years, four (4) years, and five (5) years. | Local recurrence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cosmetic outcomes for patients treated for NMSC | (1) month, three (3) months, six (6) months, one (1) year, two (2) years, three (3) years, four (4) years, and five (5) years. | Cosmetic outcomes |
| Occurrence of radiation therapy related skin toxicities | 1, 3, 6 months, and 1, 2, 3, 4, and 5 years | Skin toxicities |
Countries
United States
Outcome results
None listed